Impact of the Inflation Reduction Act on Medicare Oncology Reimbursement
The Financial Toll of the Inflation Reduction Act on Oncology Practices
The Inflation Reduction Act could impose an alarming $12 billion loss to community oncology practices by 2032, primarily impacting Medicare reimbursements under Part B. A new report by Avalere Health, commissioned by the Community Oncology Alliance (COA), highlights the severe implications of the IRA on oncology reimbursement.
Expected Reductions in Payments
- Oncologists may face a 39% to 64% decrease in Medicare add-on payments.
- Commercial and Medicare Advantage payments could see reductions of 13% to 21%.
As the report reveals, without intervention, practices may struggle to provide critical care, especially as inflation exacerbates treatment cost challenges.
Call to Action for Congressional Intervention
COA leaders have expressed alarm, urging for necessary changes to legislation to protect independent practices from the adverse effects of the IRA.
For further details on this essential topic, visiting additional resources is recommended.
Disclaimer: The information provided on this site is for informational purposes only and is not intended as medical advice. We are not responsible for any actions taken based on the content of this site. Always consult a qualified healthcare provider for medical advice, diagnosis, and treatment. We source our news from reputable sources and provide links to the original articles. We do not endorse or assume responsibility for the accuracy of the information contained in external sources.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.